Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 2, 1997, Pages 395-420

  Lynch III, Joseph P ^a,b   McCune, W Joseph ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE;

BLOOD TOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FIBROSING ALVEOLITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG SARCOIDOSIS; PRIORITY JOURNAL; REVIEW; STOMATITIS; TERATOGENESIS; WEGENER GRANULOMATOSIS;

EID: 0031045160     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.2.9032171     Document Type: Review

References (353)

1. Lynch, J. P., III, and A. D. Chavis. 1992. Chronic interstitial pulmonary disorders. In L. Victor, editor. Clinical Pulmonary Disorders. Little, Brown and Co., Boston. 193-264.
2. Lynch, J. P., and G. W. Hunninghake. 1992. Sarcoidosis. In L. M. Lichtenstein and A. S. Fauci, editors. Current Therapy in Allergy, Immunology, and Rheumatology. Mosby Year Book, Philadelphia. 243-251.
3. Fox, D. A., and W. J. McCune. 1994. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 20:265-299.
4. McCune, W. J. , D. K. Vallance, and J. P. Lynch. 1994. Immunosuppressive drug therapy. Curr. Opin. Rheumatol. 6:262-272.
5. Steinberg, A. D. 1993. Chlorambucil in the treatment of patients with immune-mediated rheumatic diseases. Arthritis Rheum. 36:325-328.
6. Faulds, D., K. L. Goa, and P. Benfield. 1993. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 45:953-1040.
7. Weinblatt, M. E. 1995. Methotrexate for chronic diseases in adults. N. Engl. J. Med. 332:330-331.
8. Boumpas, D. T., G. P. Chrousos, R. L. Wilder, T. R. Cupps, and J. E. Balow. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119:1198-1208.
9. Baxter, J. D. 1990. Minimizing the side effects of glucocorticoid therapy. Adv. Intern. Med. 35:173-194.
10. Fauci, A. S., B. F. Haynes, P. Katz, and S. M. Wolff. 1983. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 98:76-85.
11. Hoffman, G. S., G. S. Kerr, R. Y. Leavitt, C. W. Hallahan, R. S. Lebovics, W. D. Travis, M. Rottem, and A. S. Fauci. 1992. Wegener's granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116: 488-498.
12. Guillevin, L., F. Lhote, M. Gayraud, and P. Cohen. 1996. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. Medicine 75:17-28.
13. Guillevin, L., F. Lhote, P. Cohen, and B. Jarrousse. 1995. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. Arthritis Rheum. 38:1638-1645.
14. Sneller, M. C., G. S. Hoffman, C. Talar-Williams, G. S. Kerr, C. W. Hallahan, and A. S. Fauci. 1995. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. 38:608-613.
15. Johnston, I. D., S. A. Gomm, and A. Kalra. 1993. The management of cryptogenic fibrosing alveolitis in three regions in the United Kingdom. Eur. Respir. J. 6:891-893.
16. Agusti, C., A. Xaubet, A. G. N. Agusti, J. Roca, J. Ramirez, and R. Rodriquez-Roisin. 1994. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3-year followup. Eur. Respir. J. 7:643-650.
17. Boomars, K. A., S. S. Wagenaar, P. G. Mulder, H. van Velzen-Blad, and J. M. van den Bosch. 1995. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 50:1087-1092.
18. Meier-Sydow, J., M. Rust, H. Kronenberger, C. I. Thiel, M. Anthor, and H. Riemann. 1979. Long-term follow-up of lung function with parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or D-penicillamine. Prax. Pneumol. 33:680-688.
19. van Oortegem, K., B. Wallaert, C. H. Marquette, and P. Ramon. 1994. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur. Respir. J. 7:1950-1957.
20. Raghu, G., W. J. DePaso, K. Cain, S. Kammar, C. E. Wetzel, D. F. Dreis, J. Hutchinson, N. E. Pardee, and R. H. Winterbauer. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled trial. Am. Rev. Respir. Dis. 144:291-296.
21. Johnson, M. A., S. Kwan, N. J. C. Snell, A. J. Nunn, J. H. Darbyshire, and M. Turner-Warwick. 1989. Randomized, controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination with cryptogenic fibrosing alveolitis. Thorax 44:280-288.
22. Winterbauer, R. H., S. P. Hammer, K. O. Hallman, J. E. Hays, N. E. Pardee, E. H. Morgan, J. D. Allen, K. D. Moores, W. Bush, and J. H. Walker. 1978. Diffuse interstitial pneumonitis: clinicopathological correlations in 20 patients treated with prednisone/azathioprine. Am. J. Med. 656:661-672.
23. Lynch, J. P., III, and G. W. Hunninghake. 1992. Pulmonary complications of collagen vascular disease. Annual Review of Medicine 43:17-35.
24. Lower, E. E., and R. P. Baughman. 1995. Prolonged use of methotrexate for sarcoidosis. Arch. Intern. Med. 155:846-851.
25. Baughman, R. P., and E. E. Lower. 1992. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 102:1090-1094.
26. Martinet, Y., P. Pinkston, C. Saltini, J. Spurzem, J. Muller-Quernheim, and R. G. Crystal. 1988. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T lymphocyte alveolitis of active pulmonary sarcoidosis. Am. Rev. Respir. Dis. 138:1242-1248.
27. Lin, J. L., M. Wei, and Y. C. Liu. 1996. Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: a preliminary report. Thorax 51:661-663.
28. Busse, W. W., K. McGill, and N. N. Jarjour. 1996. Current management of asthma patients with corticosteroid resistance. Am. J. Respir. Crit. Care Med. 154:S70-S73.
29. Lock, S. H., A. B. Kay, and N. C. Barnes. 1996. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am. J. Respir. Crit. Care Med. 153:509-514.
30. Hill, J. M., and A. E. Tattersfield. 1995. Corticosteroid sparing agents in asthma. Thorax 50:577-582.
31. Hunninghake, G. W., and A. R. Kalica. 1995. Approaches to the treatment of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 151:915-918.
32. Watts, R. A., D. M. Carruthers, and D. G. Scott. 1995. Epidemiology of systemic vasculitis: changing incidence or definition? Semin. Arthritis Rheum. 25:28-34.
33. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150:967-972.
34. Steen, V. D., J. K. Lanz, C. Conte, G. R. Owens, and T. A. Medsger, Jr. 1994. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum. 37:1290-1296.
35. Akesson, A., A. Scheja, A. Lundin, and F. A. Wollheim. 1994. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 37:729-735.
36. Silver, R. M., J. H. Warrick, M. B. Kinsella, L. S. Staudt, M. H. Baumann, and C. Strange. 1993. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J. Rheumatol. 20:838-844.
37. Scott, D. G., and P. A. Bacon. 1980. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 35:725-732.
38. Vallance, D., J. P. Lynch, and W. J. McCune. 1995. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Curr. Opin. Rheum. 7:174-182.
39. Baughman, R.P., E. E. Lower, and J. P. Lynch. 1994. Treatment modalities for sarcoidosis. Clin. Pulm. Med. 1:223-231.
40. Lock, S. H., N. C. Barnes, and A. B. Kay. 1994. Cyclosporin A (CsA) as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Eur. Respir. J. 18(S):282s.
41. Calderon, E. C., R. F. Lockey, S. C. Bukantz, R. G. Coffey, and D. K. Ledford. 1992. Is there a role for cyclosporine in asthma? J. Allergy Clin. Immunol. 89:629-636.
42. Mullarkey, M. F., B. A. Blumenstein, W. P. Andrade, G. A. Bailey, I. Olason, and C. E. Wetzel. 1988. Methotrexate in the treatment of corticosteroid-dependent asthma: a double-blind crossover study. N. Engl. J. Med. 318:603-607.
43. Mullarkey, M. F., J. K. Lammert, and B. A. Blumenstein. 1990. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann. Intern. Med. 112:577-581.
44. Trigg, C. J., and R. J. Davies. 1993. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week, double-blind, crossover study. Respir. Med. 87:211-216.
45. Coffey, M. J., G. Sanders, W. L. Eschenbacher, A. Tsien, S. Ramesh, R. W. Weber, G. B. Toews, and W. J. McCune. 1994. The role of methotrexate in the management of steroid-dependent asthma. Chest 105:117-121.
46. Shiner, R. J., A. J. Nunn, K. F. Chung, and D. M. Geddes. 1990. Randomized, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 336:137-140.
47. Erzurum, S. C., J. A. Leff, J. E. Cochran, L. M. Ackerson, S. J. Szefler, R. J. Martin, and G. R. Cott. 1991. Lack of benefit of methotrexate in steroid-dependent asthma: a double-blind, placebo-controlled study. Ann. Intern. Med. 114:353-360.
48. Goodman, T. A., and R. P. Polisson. 1994. Methotrexate: adverse reactions and major toxicities. Rheum. Dis. Clin. North Am. 20:513-528.
49. Schnabel, A., and W. L. Gross. 1994. Low-dose methotrexate in rheumatic diseases: efficacy, side effects, and risk factors for side effects. Semin. Arthritis Rheum. 23:310-327.
50. Frasier, L. H., S. Kanekai, and J. P. Kehrer. 1991. Cyclophosphamide toxicity: characterizing and avoiding the problem. Drugs 42:781-795.
51. Morice, A. H., and W. K. Lai. 1995. Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate. Thorax 50:1221-1222.
52. Huynh-Do, U., H. Gantenbein, and U. Binswanger. 1995. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch. Intern. Med. 155:872-874.
53. Bradley, J. D., K. D. Brandt, and B. P. Katz. 1989. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum. 32:45-53.
54. Kim, J. H., and J. R. Perfect. 1989. Infection and cyclosporine. Rev. Infect. Dis. 11:677-690.
55. LeMense, G. P., and S. A. Sahn. 1994. Opportunistic infection during treatment with low-dose methotrexate. Am. J. Respir. Crit. Care Med. 150:258-260.
56. Baker, G. L., L. E. Kahl, B. C. Zee, B. L. Stolzer, A. K. Agarwal, and T. A. Medsger, Jr. 1987. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am. J. Med. 83:1-9.
57. Palmer, R. G., C. J. Drey, and A. M. Denman. 1984. Chlorambucil-induced chromosomal damage to human lymphocytes is dose dependent and cumulative. Lancet 1:246-249.
58. Smith, A. G., A. G. Prentice, N. P. Lucie, J. D. Browning, J. H. Dagg, and R. M. Rowan. 1982. Acute myelogenous leukaemia following cytotoxic therapy: five cases and a review. Q. J. Med. S1:227-240.
59. Cockburn, I., and P. Krupp. 1989. The risk of neoplasms in patients treated with cyclosporin A. J. Autoimmun. 2:723-731.
60. Penn, I. 1987. Cancers following cyclosporine therapy. Transplant. Proc. 19:2211-2213.
61. Kamel, O. W., M. van de Rijn, L. M. Weiss, G. J. Del Zoppo, P. K. Hench, B. A. Robbins, P. G. Montgomery, R. A. Warnke, and R. F. Dorfman. 1993. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 328:1317-1321.
62. Talar-Williams, C., Y. M. Hijazi, M. M. Walther, W. M. Linehan, C. W. Hallahan, I. Lubensky, G. S. Kerr, G. S. Hoffman, A. S. Fauci, and M. C. Sneller. 1996. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann. Intern. Med. 124:477-484.
63. Travis, L. B., R. E. Curtis, B. Glimelius, E. J. Holowaty, F. E. Van Leeuwen, C. F. Lynch, A. Hagenbeek, M. Stovall, P. M. Banks, J. Adami, et al. 1995. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 87:524-530.
64. Arellano, F., and P. Krupp. 1993. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br. J. Rheumatol. 32(S1): 72-75.
65. Radis, C. D., L. E. Kahl, G. L. Baker, M. C. Wasko, J. M. Cash, A. Gallatin, B. L. Stolzer, A. K. Agarwal, T. A. Medsger, Jr., and C. K. Kwoh. 1995. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum. 38: 1120-1127.
66. Van der Veen, M. J., J. J. Dekker, H. J. Dinand, R. M. van Soesbergen, and J. W. Bijlsma. 1995. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 22:1766-1768.
67. Refabert, L., P. Sinnassamy, B. Leroy, B. Fauroux, J. de Blic, and A. Bensman. 1995. Azathioprine-induced pulmonary hemorrhage in a child after renal transplantation. Pediatr. Nephrology 9:470-473.
68. Sen, R. P., T. E. Walsh, W. Fisher, and N. Brock. 1991. Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 99:143-146.
69. Barrera, P., R. F. Laan, P. L. van Riel, P. N. Dekhuijzen, A. M. Boerbooms, and L. B. van de Putte. 1994. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann. Rheum. Dis. 53: 434-439.
70. Cottin, V., J. Tebib, B. Massonnet, P. J. Souquet, and J. P. Bernard. 1996. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 109:933-938.
71. Levey, A. S., S. P. Lan, H. L. Corwin, B. S. Kasinath, J. Lachin, E. G. Neilson, L. G. Hunsicker, and E. J. Lewis. 1992. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann. Intern. Med. 116:114-123.
72. McCune, W. J., J. Golbus, W. Zeldes, P. Bohlke, R. Dunne, and D. A. Fox. 1988. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318:1423-1431.
73. Neuwelt, C. M., S. Lacks, B. R. Kaye, J. B. Ellman, and D. G. Boroenstein. 1995. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98:32-46.
74. Dalakas, M. C. 1992. Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin. Neuropharmacol. 15:327-351.
75. Faedda, R., A. Satta, F. Tanda, M. Pirisi, and E. Bartoli. 1994. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 67:59-65.
76. Falk, R. J., S. L. Hogan, K. E. Muller, and J. C. Jennette. 1992. Treatment of progressive membranous glomerulopathy: a randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann. Intern. Med. 116:438-445.
77. Hamuryudan, V., S. Yurdakul, F. Moral, F. Numan, H. Tuzun, N. Tuzuner, C. Mat, Y. Tuzun, Y. Ozyazgan, and H. Yazici. 1994. Pulmonary arterial aneurysms in Behcet's syndrome: a report of 24 cases. Br. J. Rheumatol. 33:48-51.
78. Turner-Warwick, M., and P. L. Haslam. 1987. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am. Rev. Respir. Dis. 135:26-34.
79. O'Donnell, K., B. Keogh, A. Cantin, and R. G. Crystal. 1987. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 136: 288-292.
80. Dayton, C. S., D. A. Schwartz, R. A. Helmeers, R. J. Pueringer, S. R. Gilbert, R. K. Merchant, and G. W. Hunninghake. 1993. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 103:69-73.
81. Rudd, R. M., P. L. Haslam, and M. Turner-Warwick. 1981. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am. Rev. Respir. Dis. 124:1-8.
82. Schwartz, D. A., D. S. Van Fossen, C. S. Davis, R. A. Helmers, C. S. Dayton, L. F. Burmeister, and G. W. Hunninghake. 1994. Determinants of progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 149:444-449.
83. Fort, J. G., H. Scovern, and J. L. Abruzzo. 1988. Intravenous cyclophosphamide and methylprednisolone for the treatment of bronchiolitis obliterans and interstitial fibrosis associated with cryotherapy. J. Rheumatol. 15:850-854.
84. Martinez, J. P., and J. P. Lynch, III. 1994. Collagen vascular disease-associated bronchiolitis obliterans organizing pneumonia. In G. R. Epler, editor. Diseases of the Bronchioles. Raven Press, New York. 347-366.
85. Demeter, S. L. 1988. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest 94:202-203.
86. Hunninghake, G. W., S. Gibert, R. Puriner, C. Dayton, C. Floerchinger, R. Helmers, R. Merchant, J. Wilson, J. Galvin, and D. Schwartz. 1994. Outcome of the treatment for sarcoidosis. Am. J. Respir. Crit. Care Med. 149:893-898.
87. Cupps, T. R., L. C. Edgar, and A. S. Fauci. 1982. Suppression of human B lymphocyte function by cyclophosphamide. J. Immunol. 128:2453-2457.
88. Yasunami, R., and J. F. Bach. 1988. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur. J. Immunol. 18:481-484.
89. Hoffman, G. S., R. Y. Leavitt, T. A. Fleisher, J. R. Minor, and A. S. Fauci. 1990. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am. J. Med. 89:403-410.
90. Drosos, A. A., L. I. Sakkas, A. Goussia, K. C. Siamopoulos, and H. M. Moutsopoulos. 1992. Pulse cyclophosphamide therapy in Wegener's granulomatosis: a pilot study. J. Intern. Med. 232:279-282.
91. Le Thi Huong, D., T. Pap, J. C. Piette, B. Wechsler, C. F. Lynch, and A. Hagenbeek. 1996. Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis. Clin. Exp. Rheumatol. 14:9-16.
92. Zonzitis, E., W. Aberer, and G. Tappeiner. 1992. Drug eruptions from mesna after cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis. Arch. Dermatol. 128: 80-82.
93. McCune, W. J., and A. W. Friedman. 1993. Immunosuppressive drug therapy for rheumatic disease. Curr. Opin. Rheum. 5:282-292.
94. Guillevin, L., B. Jarrousse, C. Lok, F. Lhote, J. P. Jais, D. Le Thi Huong Du, and A. Bussel. 1991. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: a prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J. Rheumatol. 18:567-574.
95. Bridges, A. J., and R. P. Burns. 1992. Acute iritis associated with primary Sjogren's syndrome and high-titer anti-SS-A/Ro and anti-SS-B/La antibodies: treatment with combination immunosuppressive therapy. Arthritis Rheum. 35:560-563.
96. Reinhold-Keller, E., J. Kekow, A. Schnabel, W. H. Schmitt, M. Heller, A. Beigel, G. Duncker, and W. L. Gross. 1994. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 37:919-924.
97. Genereau, T., O. Lortholary, P. Leclerq, D. Grenet, M. Tubery, D. Sicard, I. Caubbarrere, and L. Guillevin. 1994. Treatment of systemic vasculitis and cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br. J. Rheumatol. 33:959-962.
98. Godeau, B., C. Cormier, and C. J. Menkes. 1991. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann. Rheum. Dis. 50:956-958.
99. Eiser, A. R., and H. M. Shanies. 1994. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum. 37:428-431.
100. Fox, D. A., and W. J. McCune. 1989. Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. Concepts Immunopathol. 7:20-78.
101. Cronin, M. E., F. W. Miller, J. E. Hicks, M. Dalakas, and P. H. Plotz. 1989. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J. Rheumatol. 16:1225-1228.
102. Vaiopoulos, G., P. P. Sfikakis, B. Skoumas, E. Kavouklis, E. Doukas, and P. Kaklamanis. 1994. Lack of response to corticosteroids and pulse cyclophosphamide therapy in Cogan's syndrome. Clin. Rheumatol. 13:110-112.
103. Trillet-Lenoir, V., J. Green, C. Manegold, J. Von Pawel, U. Gatzemeier, B. Lebeau, A. Depierre, P. Johnson, G. Decoster, D. Tomita, et al. 1993. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 29A:319-324.
104. Gabrilove, J. L., A. Jakubowski, H. Scher, C. Sternberg, G. Wong, J. Grous, A. Yagoda, K. Fain, M. A. S. Moore, B. Clarkson, H. F. Oettgen, K. Alton, K. Welte, and L. Souza. 1988. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med. 318:1414-1422.
105. Moder, K. G., A. Tefferi, M. D. Cohen, D. M. Menke, and H. S. Luthra. 1995. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am. J. Med. 99:276-281.
106. Herrstedt, J., T. Sigsgaard, M. Boesgaard, T. P. Jensen, and P. Dombernowsky. 1993. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N. Engl. J. Med. 328:1076-1080.
107. Campora, E., S. Giudici, L. Merlini, A. Rubagotti, and R. Rosso. 1994. Ondansetron and dexamethasone versus standard combination antiemetic therapy: a randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am. J. Clin. Oncol. 17:522-526.
108. Levitt, M., D. Warr, L. Yelle, H. L. Rayner, W. S. Lofters, D. J. Perrault, K. S. Wilson, J. Latreille, M. Potvin, E. Warner, et al. 1993. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cy-clophosphamide, methotrexate, and fluorouracil. N. Engl. J. Med. 328:1081-1084.
109. Le Thi Huong Du, D., D. Rigaud, T. Papo, and P. Godeau. 1994. Cyclophosphamide-induced hepatitis in Wegener's granulomatosis. Mayo Clin. Proc. 69:912-913.
110. Snyder, L. S., and M. L. Anderson. 1993. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin. Proc. 68:1203-1204.
111. Stentoft, J. 1987. Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med. Scand. 221:403-407.
112. Stillwell, T. J., and R. C. Benson, Jr. 1988. Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer 61:451-457.
113. Plotz, P. H., J. H. Klippel, J. L. Decker, D. Grauman, B. Wolff, B. C. Brown, and G. Rutt. 1979. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann. Intern. Med. 91:221-223.
114. Elliot, R. W., D. M. Essenhigh, and A. R. Morley. 1982. Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. B.M.J. 284:1160-1161.
115. Pedersen-Bjergaard, J., J. Ersboli, H. M. Sorensen, N. Keiding, S. O. Larsen, P. Philip, M. S. Larsen, H. Schultz, N. I. Niessen, J. Ersbll, and H. M. Svensen. 1985. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann. Intern. Med. 103:195-200.
116. Fairchild, W. V., C. R. Spence, H. D. Solomon, and M. P. Gangai. 1979. The incidence of bladder cancer after cyclophosphamide therapy. J. Urol. 122:163-164.
117. Pedersen-Bjergaard, J., J. Ersboli, V. L. Hansen, H. M. Sorensen, et al. 1988. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N. Engl. J. Med. 318:1028-1032.
118. Austin, H. A., J. H. Klippel, J. E. Balow, N. G. le Riche, A. D. Steinberg, P. H. Plotz, and J. L. Decker. 1986. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314:614-619.
119. Kinlen, L. J. 1985. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am. J. Med. 78:44-49.
120. Gmelig-Meyling, F., S. Dawisha, and A. D. Steinberg. 1992. Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J. Exp. Med. 175:297-300.
121. Baltus, J. A., J. W. Boersma, A. P. Hartman, and J. P. Vandenbroucke. 1983. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann. Rheum. Dis. 42:368-373.
122. Schneider, V., S. Kay, and H. M. Lee. 1983. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytologica 27:220-224.
123. Ataya, K. M., F. A. Valeriote, and A. J. Ramahi-Ataya. 1989. Effect of cyclophosphamide on the immature rat ovary. Cancer Res. 49: 1660-1664.
124. Koyama, H., T. Wada, Y. Nishizawa, T. Iwanaga, and Y. Aoki. 1977. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409.
125. Chapman, R. M., and S. B. Sutcliffe. 1981. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 58:849-851.
126. Hoorweg-Nijman, J. J., H. A. Delemarre-Van de Waal, F. C. de Waal, and H. Behrendt. 1992. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol. 126:143-148.
127. Bermas, B. L., and J. A. Hill. 1995. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 38:1722-1732.
128. Dow, E., H. Schulman, and E. Agura. 1993. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 12:169-172.
129. Meier-Sydow, J., S. M. Weiss, R. Buhl, M. Rust, and G. Raghu. 1994. Idiopathic pulmonary fibrosis: current concepts and challenges in management. Semin. Respir. Crit. Care Med. 15:77-96.
130. Behr, J., C. Vogelmeier, T. Beinert, M. Meurer, F. Kormbach, G. Koning, and G. Fruhmann. 1996. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am. J. Respir. Crit. Care Med. 154:400-406.
131. Wells, A. U., D. M. Hansell, M. B. Rubens, P. Cullinan, C. M. Black, and R. M. Du Bois. 1993. The predictive value of appearances on thin section computed tomography in fibrosing alveolitis. Am. Rev. Respir. Dis. 148:1076-1082.
132. Wells, A. U., D. H. Hansell, M. B. Rubens, P. Cullinan, P. L. Haslam, C. M. Black, and R. M. DuBois. 1994. Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearance. Am. J. Respir. Crit. Care Med. 150:462-468.
133. McDonagh, J., M. Greaves, A. R. Wright, C. Heycock, J. P. Owen, and C. Kelly. 1994. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 33:118-122.
134. Raghu, G. 1995. Interstitial lung disease: a diagnostic approach - are CT scan and lung biopsy indicated in every patient? Am. J. Respir. Crit. Care Med. 151:909-914.
135. Hemady, R., J. Tauber, and C. S. Foster. 1991. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv. Ophthalmol. 35:369-385.
136. Reichert, L. J., F. T. Huysmans, K. Assmann, R. A. Koene, and J. F. Wetzels. 1994. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann. Intern. Med. 121: 328-333.
137. Niaudet, P., for the French Society of Pediatric Nephrology. 1992. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Pediatr. Nephrology 6:1-3.
138. Sinoway, P. A., and J. P. Callen. 1993. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 36:319-324.
139. Cannon, G. W., C. G. Jackson, C. O. Saumualson, J. R. Ward, H. J. Williams, and D. O. Clegg. 1985. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin. Arthritis Rheum. 15:106-118.
140. Israel, H. L., and A. S. Patchefsky. 1975. Treatment of Wegener's granulomatosis of the lung. Am. J. Med. 58:671-674.
141. Clements, P., P. Lachenbruch, D. Furst, and H. Paulus. 1993. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum. 36:1575-1579.
142. Furst, D. E., P. J. Clements, S. Hillis, P. A. Lachenbruch, B. L. Miller, M. G. Sterz, and H. E. Paulus. 1989. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 32:584-593.
143. Hughes, G. S., Y. P. Kataria, and T. F. O'Brien. 1983. Sarcoidosis presenting as biliary cirrhosis: treatment with chlorambucil. South. Med. J. 76:1440-1442.
144. Kataria, Y. P. 1980. Chlorambucil in sarcoidosis. Chest 78:36-43.
145. Israel, H. L., D. W. Fouts, and R. A. Beggs. 1973. A controlled trial of prednisone in sarcoidosis. Am. Rev. Respir. Dis. 110:609-614.
146. Chiappelli, F., L. W. Myers, G. W. Ellison, D. Liao, and J. L. Fahey. 1991. Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: studies in patients with chronic progressive multiple sclerosis. Int. J. Immunopharmacol. 13:455-461.
147. Mohr, M., D. Kingreen, H. Ruhl, and D. Huhn. 1993. Interstitial lung disease: an underdiagnosed side effect of chlorambucil? Ann. Hematol. 67:305-307.
148. Crestani, B., A. Jaccard, D. Israel-Biet, L. J. Couderc, J. Frija, and J. P. Clauvel. 1994. Chlorambucil-associated pneumonitis. Chest 105:634-636.
149. Berk, P. D., J. D. Goldberg, M. N. Silverstein, A. Weinfield, P. B. Donovan, J. T. Ellis, S. A. Landaw, J. Laslo, Y. Najean, A. B. Pisciotta, and L. J. Wasserman. 1981. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Engl. J. Med. 304:441-447.
150. Patapanian, H., S. Graham, P. N. Sambrook, C. D. Browna, G. D. Champion, M. L. Cohen, and R. O. Day. 1988. The oncogenicity of chlorambucil in rheumatoid arthritis. Br. J. Rheumatol. 27:44-47.
151. Elzouki, A. Y., K. Al-Nassar, M. Al-Ali, G. Malik, F. Elsharie, and O. P. Jaiswal. 1991. Sister chromatid exchange analysis in monitoring chlorambucil therapy in primary nephrotic snydrome of childhood. Pediatr. Nephrology 5:59-61.
152. Palmer, R. G., and A. M. Denman. 1984. Malignancies induced by chlorambucil. Cancer Treat. Rev. 11:121-129.
153. Hoffman, G. S., R. Y. Leavitt, G. S. Kerr, and A. S. Fauci. 1992. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 35:1322-1329.
154. Danao, T., T. Ropos, W. Wilke, A. Segal, L. Calabrese, R. Valenzuela, L. Gragg, and J. Clough. 1992. Nitrogen mustard as induction therapy for rheumatoid arthritis: clinical and immunologic effects. J. Rheumatol. 19:1683-1686.
155. Rossman, M., and J. R. Bertino. 1973. Azathioprine. Ann. Intern. Med. 79:694-698.
156. Spina, C. A. 1984. Azathioprine as an immune modulating drug: clinical applications. Clin. Immunol. Allergy 4:415-446.
157. Pearson, D. C., G. R. May, G. H. Fick, and L. R. Sutherland. 1995. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann. Intern. Med. 122:132-142.
158. Candy, S., J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman. 1995. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37:674-678.
159. Johnson, P. J., I. G. McFarlane, and R. Williams. 1995. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med. 333:958-963.
160. Pacheco, Y., C. Marechal, F. Marechal, N. Biot, and M. Perrin-Fayolle. 1985. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 2:107-113.
161. Sharma, O., D. T. D. Hughes, D. G. James, and P. Naish. 1971. Immunosuppressive therapy with azathioprine in sarcoidosis. In L. Levinsky and F. Macholoa, editors. Fifth International Conference on Sarcoidosis and Other Granulomatous Disorders. Universita Karlova, Prague. 635-637.
162. McCarty, M. J., P. Lillis, and S. J. Vukelja. 1996. Azathioprine as a steroid-sparing agent in radiation pneumonitis. Chest 109:1397-1400.
163. Costabel, U., and H. Matthys. 1981. Different therapies and factors influencing response to therapy in idiopathic diffuse fibrosing alveolitis. Respiration 42:141.
164. Sandborn, W. J., O. Van, B. J. Zins, W. J. Tremaine, D.C. Mays, and J. J. Lipsky. 1995. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109:1808-1817.
165. Present, D. H., S. J. Meltzer, M. P. Krumholz, A. Wolke, and B. I. Korelitz. 1989. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. 111:641-649.
166. Singh, G., J. F. Fries, P. Spitz, and C. A. Williams. 1989. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum. 32:837-843.
167. Connell, W. R., M. A. Kamm, J. K. Ritchie, and J. E. Lennard-Jones. 1993. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34:1081-1085.
168. Kerstens, P. J., J. N. Stolk, R. A. De Abreu, L. H. Lambooy, L. B. van de Putte, and A. A. Boerbooms. 1995. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38:142-145.
169. Sterneck, M., R. Wiesner, N. Ascher, J. Roberts, L. Ferrell, J. Ludwig, and J. Lake. 1991. Azathioprine hepatotoxicity after liver transplantation. Hepatology 14:806-810.
170. Jones, M. C., P. V. Best, and G. R. D. Catto. 1988. Is nodular
171. Adler, M., M. Delhaye, C. Deprez, N. Hardy, M. Gelin, L. De Pauw, P. Vereerstraeten, M. Cremer, and C. Toussaint. 1987. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Nephrol. Dial. Transplant. 2:183-188.
172. Liano, F., A. Moreno, R. Matesanz, J. L. Teruel, C. Redondo, F. Garcia-Martin, L. Orte, and J. Ortuno. 1989. Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause? Nephron 51:509-516.
173. Lemley, D., L. Delacy, L. Seeff, K. Ishak, and D. Nashel. 1989. Azathioprine-induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann. Rheum. Dis. 48:342-346.
174. Kinlen, L. J. 1992 Malignancy in autoimmune diseases. Autoimmunity 5:363-371.
175. Bottomley, W. W., G. Ford, W. J. Cunliffe, and J. A. Cotterill. 1995. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br. J. Dermatol. 133:460-462.
176. Balachandran, I., and K. S. Galagan. 1984. Cervical carcinoma in situ associated with azathioprine therapy: a case report and literature review. Acta Cytologica 28:699-702.
177. Silman, A. J., J. Petri, B. Hazleman, and S. J. W. Evans. 1988. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann. Rheum. Dis. 47:988-992.
178. Tage-Jensen, U., T. Schlichting, H. F. Thomsen, and C. Thomsen. 1987. Malignancies following long-term azathioprine treatment in chronic liver disease. Liver 7:81-83.
179. Wilkinson, A. H., J. L. Smith, L. G. Hunsicker, J. Tobacman, D. P. Kapelanski, M. Johnson, F. H. Wright, D. M. Behrendt, and R. J. Corry. 1989. Increased frequency of post-transplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplantation 47:293-296.
180. Wang, K. K., A. J. Czaja, S. J. Beaver, and V. L. Go. 1989. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 10:39-43.
181. Connell, W. R., M. A. Kamm, M. Dickson, A. M. Balkwill, J. K. Ritchie, and J. E. Lennard-Jones. 1994. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249-1252.
182. Amato, M. P., G. Pracucci, G. Ponziani, G. Siracusa, L. Fratiglioni, and L. Amaducci. 1993. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 43:831-833.
183. Voogd, C. E. 1989. Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutat. Res. 221:133-152.
184. Kirk, E. P. 1991. Organ transplantation and pregnancy: a case report and review. Am. J. Obstet. Gynecol. 164:1629-1634.
185. DeWitte, D. B., M. K. Buick, S. E. Cyran, and M. J. Maisels. 1984. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J. Pediatr. 105:625-628.
186. Davison, J. M., H. Dellagrammatikas, and J. M. Parkin. 1985. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. Br. J. Obstet. Gynecol. 92:233-239.
187. Baxi, L. V., and R. B. Rho. 1993. Pregnancy after cardiac transplantation. Am. J. Obstet. Gynecol. 169:33-34.
188. Brown, C. H., and M. Turner-Warwick. 1971. The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs. Q. J. Med. 158:289-302.
189. Weese, W. C., B. W. Levine, and H. Kazemi. 1975. Interstitial lung disease resistant to corticosteroid therapy: report of three cases treated with azathioprine or cyclophosphamide. Chest 67:57-60.
190. Kahan, B. D. 1989. Cyclosporine. N. Engl. J. Med. 321:1725-1738.
191. Cohen, D. J., R. Lertscher, M. F. Rubin, N. L. Tilney, C. B. Carpenter, and T. B. Strom. 1984. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 101:667-682.
192. Austin, H. A., III, A. G. Palestine, S. G. Sabnis, J. E. Balow, H. G. Preuss, R. B. Nussenblatt, and T. T. Antonovych. 1989. Evolution of cyclosporin nephrotoxicity in patients treated for autoimmune uveitis. Am. J. Nephrol. 9:392-402.
193. Masuda, K., A. Nakajima, A. Urayama, K. Nakae, M. Kogure, and G. Inaba. 1989. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1:1093-1096.
194. Ellis, C. N., M. S. Fradin, J. M. Messana, M. D. Brown, M. T. Siegel, A. H. Hartley, L. L. Rocher, S. Wheeler, T. A. Hamilton, and T. G. Parish. 1991. Cyclosporine for plaque-type psoriasis. N. Engl. J. Med. 324:277-284.
195. Gupta, A. K., C. N. Ellis, B. J. Nickoloff, M. T. Goldfarb, V. C. Ho, L. L. Rocher, C. E. Griffiths, K. D. Cooper, and J. J. Voorhees. 1990. Oral cyclosporine in the treatment of inflammatory and non-inflammatory dermatoses. Arch. Dermatol. 126:339-350.
196. Feagan, B. G., J. W. McDonald, J. Rochon, A. Laupacis, R. N. Fedorak, D. Kinnear, F. Saibil, A. Groll, A. Archambault, and R. Gillies. 1994. Low-dose cyclosporine for the treatment of Crohn's disease. N. Engl. J. Med. 330:1846-1851.
197. Lichtiger, S., D. H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, F. Michelassi, and S. Hanauer. 1994. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330:1841-1845.
198. Hanauer, S. B., and M. B. Smith. 1993. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am. J. Gastroenterol. 88:646-649.
199. Sandborn, W. J., and W. J. Tremaine. 1992. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. 67:981-990.
200. Wiesner, R. H., J. Ludwig, K. D. Lindor, R. A. Jorgensen, W. P. Baldus, H. A. Homburger, and E. R. Dickson. 1990. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 322:1419-1424.
201. Ahern, M. J., W. Harrison, P. Hollingsworth, J. Bradley, B. Laing, and C. Bayliss. 1991. A randomized double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust. N.Z. J. Med. 21:844-849.
202. Yocum, D. E., and H. Torley. 1995. Cyclosporine in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21:835-844.
203. Tindall, R. S., J. A. Rollins, J. T. Phillips, R. G. Greenlee, L. Wells, and G. Belendiuk. 1987. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 315:719-724.
204. Alton, E. W., M. Johnson, and M. Turner-Warwick. 1989. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir. Med. 83:277-279.
205. Fukazawa, M., M. Kawano, S. Hisano, K. Veda, and K. Matsuba. 1990. Efficacy of cyclosporine A for idiopathic pulmonary fibrosis. Eur. J. Pediatr. 149:441-442.
206. Moolman, J. A., P. G. Bardin, D. J. Rossouw, and J. R. Joubert. 1991. Cyclosporin as a treatment for interstitial lung disease of unknown etiology. Thorax 46:592-595.
207. Venuta, F., E. A. Rendina, P. Ciriaco, T. De Giacomo, E. Pompeo, A. Bachetoni, and C. Ricci. 1993. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation. J. Heart Lung Transplant. 12:909-914.
208. Rebuck, A. S., D. R. Stiller, A. C. Braude, A. Laupacis, R. D. Cohen, and K. R. Chapman. 1984. Cyclosporin for pulmonary sarcoidosis. Lancet 1:1174.
209. Rebuck, A. S., B. R. Sanders, D. K. MacFadden, S. F. P. Mann, E. L. York, and R. D. Cohen. 1987. Cyclosporin in pulmonary sarcoidosis. Lancet 1:1486.
210. Stern, B. J., S. A. Schonfeld, C. Sewell, A. Krunholz, P. Scott, and G. Belendiuk. 1992. The treatment of neurosarcoidosis with cyclosporine. Arch. Neurol. 49:1065-1072.
211. Kavanaugh, A. F., S. L. Andrew, B. Cooper, E. C. Lawrence, and D. P. Huston. 1987. Cyclosporin therapy of central nervous system sarcoidosis. Am. J. Med. 82:387.
212. Chapelon, C., J. M. Ziza, J. C. Piette, Y. Levy, G. Raguin, B. Wechsler, M. O. Bitker, O. Bletry, D. Laplane, M. G. Bousser, and P. Godeau. 1990. Neurosarcoidosis: signs, course, and treatment in 345 confirmed cases. Medicine 69:261-276.
213. Gelwan, M. J., R. I. Kellen, R. M. Burde, and M. Kupersmith. 1988. Sarcoidosis of the anterior visual pathway: successes and failures. J. Neurol. Neurosurg. Psychiatry 51:1473-1480.
214. Bieloary, L., C. Holland, P. Gascon, and L. Frohman. 1988. Uveitis, cutaneous and neurosarcoid: treatment with low-dose cyclosporine A. Transplant. Proc. 20:144-148.
215. Clarke, A. E., A. Bitton, R. Eappen, D. S. Danoff, and J. M. Esdaile. 1990. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation 50:1047-1051.
216. Alexander, A. G., N. C. Barnes, and A. B. Kay. 1992. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324-328.
217. Szczeklik, A., E. Nizankowska, R. Dworski, B. Domagala, and G. Pinis. 1991. Cyclosporin for steroid-dependent asthma. Allergy 46: 312-315.
218. Nizankowska, E., J. Soja, G. Pinis, G. Bochenek, K. Sladek, B. Domagala, A. Pajak, and A. Szczeklik. 1995. Treatment of bronchial asthma with cyclosporin. Eur. Respir. J. 8:1091-1099.
219. Schreiber, S. L., and G. R. Crabtree. 1992. The mechanism of action of cyclosporine A and FK506. Immunol. Today 13:136-142.
220. Furue, M., and S. I. Katz. 1988. The effect of cyclosporine on epidermal cells: cyclosporine inhibits accessory cell function of epidermal Langerhans cells in vitro. J. Immunol. 140:4139-4143.
221. Cooper, K. D., O. Baadsgaard, C. N. Ellis, E. A. Duell, and J. J. Voorhees. 1990. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J. Invest. Dermatol. 94:649-656.
222. Ewart, S. L., S. H. Gavett, J. Margolick, and M. Wills-Karp. 1996. Cyclosporin A attenuates genetic airway hyperresponsiveness in mice but not through inhibition of CD4 + or CD8 + T cells. Am. J. Respir. Cell Mol. Biol. 14:7634-7727.
223. Watkins, P. B. 1990. The role of cytochromes P-450 in cyclosporine metabolism. J. Am. Acad. Dermatol. 23:1301-1311.
224. Lindholm A., and B. D. Kahan. 1993. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. Ther. 54:205-218.
225. Kovarik, J. M., E. A. Mueller, J. B. van Bree, W. Tetzloff, and K. Kutz. 1994. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83:444-446.
226. Mueller, E. A., J. M. Kovarik, J. B. van Bree, A. E. Lison, and K. Kutz. 1994. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 57:1178-1182.
227. Holt, D. W., J. T. Marsden, T. O. Fashola, and A. Johnston. 1992. Performance of the Sandoz radioimmunoassays for cyclosporine. Transplant. Proc. 22:1155-1159.
228. Keogh, A., P. Spratt, C. McCosker, P. Macdonald, J. Mundy, and A. Kaan. 1995. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333:628-633.
229. Ong, C. S., C. A. Pollock, R. J. Caterson, J. F. Mahony, D. A. Waugh, and L. S. Ibels. 1994. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine 73:215-223.
230. Nankivell, B. J., M. Hibbins, and J. R. Chapman. 1994. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 58:989-996.
231. Lindholm, A., and S. Henricsson. 1990. Comparative analyses of cyclosporine in whole blood and plasma by radioimmunoassay, fluorescence polarization immunoassay, and high-pressure liquid chromatography. Ther. Drug Monit. 12:344-352.
232. Timonen, P., D. Friend, K. Abeywickrama, C. Laburte, B. von Graffenried, and G. Feutren. 1990. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br. J. Dermatol. 122(Suppl. 36):33-39.
233. Christophers, E., U. Mrowietz, H. H. Henneicke, L. Farber, and D. Welzel. 1992. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis: the German Multicenter Study. J. Am. Acad. Dermatol. 26:86-90.
234. U.S. Multicenter FK506 Liver Study Group. 1994. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 331:1110-1116.
235. Textor, S. C., V. J. Canzanello, S. J. Taler, D. J. Wilson, L. L. Schwartz, J. E. Augustin, J. M. Raymer, J. C. Romero, R. H. Wiesner, and R. A. Krom. 1994. Cyclosporine-induced hypertension after transplantation. Mayo Clin. Proc. 69:1182-1193.
236. Deray, G., M. Benhmida, P. Le Hoang, P. Maksud, B. Aupetit, A. Baumelou, and C. Jacobs. 1992. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann. Intern. Med. 117:578-583.
237. Myers, B. D., L. Newton, and P. Oyer. 1991. The case against the indefinite use of cyclosporine. Transplant. Proc. 23:41-42.
238. Myers, B. D., R. Sibley, L. Newton, S. J. Tomlanovich, C. Boshkos, E. Stinson, J. A. Luetscher, D. J. Whitney, D. Krasny, N. S. Coplon, and M. G. Perlroth. 1988. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 33:590-600.
239. Porter, G. A., W. Bennett, and S. G. Sheps. 1990. Cyclosporine-associated hypertension: National High Blood Pressure Education Program. Arch. Intern. Med. 150:280-283.
240. Laskow, D. A., J. J. Curtis, R. G. Luke, B. A. Julian, P. Jones, M. H. Deierhoi, W. H. Barber, and A. G. Diethelm. 1990. Cyclosporine-induced changes in glomerular filtration rate and urea excretion. Am. J. Med. 88:497-502.
241. Weir, M. R. 1991. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am. J. Med. 90(Suppl. 5A):32S-36S.
242. Burke, J. F., Jr., J. D. Prisch, E. L. Ramos, D. R. Salomon, D. M. Stablein, D. H. Van Buren, and J. C. West. 1994. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N. Engl. J. Med. 331:358-363.
243. de Groen, P. C. 1989. Cyclosporine: a review and its specific use in liver transplantation. Mayo Clin. Proc. 64:680-689.
244. Kopp, J. B., and P. E. Klotman. 1990. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J. Am. Soc. Nephrol. 1:162-179.
245. Porayko, M. K., S. C. Textor, R. A. Krom, J. E. Hay, G. J. Gores, T. M. Richards, P. H. Crotty, S. J. Beaver, J. L. Steers, and R. H. Wiesner. 1994. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin. Proc. 69:105-111.
246. Feutren, G., and M. J. Mihatsch. 1992. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N. Engl. J. Med. 326:1654-1660.
247. Gilbert, S. C., M. Emmett, A. Menter, A. Silverman, and G. Klintmalm. 1989. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J. Am. Acad. Dermatol. 21:470-474.
248. Altman, R. D., G. O. Perez, and G. N. Sfakianakis. 1992. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am. J. Med. 93:396-402.
249. Palestine, A. G., H. A. Austin, III, J. E. Balow, T. T. Antonovych, S. G. Sabnis, H. G. Preuss, and R. B. Nussenblatt. 1996. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N. Engl. J. Med. 314:1293-1298.
250. Foley, R. J., C. T. Van Buren, R. Hamner, and E. J. Weinmann. 1983. Cyclosporine-associated hyperkalemia. Transplant. Proc. 15(Suppl. 1):510-513.
251. Thompson, C. B., C. H. June, K. M. Sullivan, and E. D. Thomas. 1984. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2:1116-1120.
252. June, C. H., C. B. Thompson, M. S. Kennedy, J. Nims, and E. D. Thomas. 1985. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation 39:620-624.
253. Mrowietz, U., L. Farber, H. Bachmann, and E. Christophers. 1992. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J. Am. Acad. Dermatol. 27:491-492.
254. Ballantyne, C. M., E. J. Podet, W. P. Patsch, Y. Harati, V. Appel, A. M. Gotto, Jr., and J. B. Young. 1989. Effects of cyclosporine therapy on plasma lipoprotein levels. J.A.M.A. 262:53-56.
255. Lowry, R. P., S. G. Solty, L. Peters, R. Mangel, and A. D. Sniderman. 1987. Type II hyperlipoproteinaemia, hyperapobetalipoproteinaemia, and hyperalphalipoproteinaemia following renal transplantation: implications for atherogenic risk. Transplant. Proc. 19:3426-3430.
256. Pirsch, J. D., A. M. D'Alessandro, H. W. Sollinger, S. J. Knechtle, A. Reed, M. Kalayoglu, and F. O. Belzer. 1992. Hyperlipidemiaand transplantation: etiologic factors and therapy. J. Am. Soc. Nephrol. 2:S238-S242.
257. Gryn, J., J. Goldberg, and E. Viner. 1992. Propranolol for the treatment of cyclosporine-induced headaches. Bone Marrow Transplant. 9:211-212.
258. de Prada, J. A. V., R. Martin-Duran, C. Garcia-Monco, J. R. Calvo, J. J. Olalla, F. Gonzalez-Vilchez, and J. A. Gutierrez. 1990. Cyclosporine neurotoxicity in heart transplantation. J. Heart Transplant. 9:581-583.
259. Rubin, A. M., and H. Kang. 1987. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 37:1072-1076.
260. Wysocki, G. P., H. A. Gretzinger, A. Laupacis, R. A. Ulan, and C. R. Stiller. 1983. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg. Oral Med. Oral Pathol. 55:274-278.
261. Reznik, V. M., K. L. Jones, B. L. Durham, and S. A. Mendoza. 1987. Changes in facial appearance during cyclosporin treatment. Lancet 1:1405-1407.
262. Schade, R. R., A. Guglielmi, D. H. Van Thiel, et al. 1983. Cholestasis in heart transplant recipients treated with cyclosporine. Transplant. Proc. 15:2757-2760.
263. Lorber, M. I., S. M. Flechner, C. T. Van Buren, K. Sorensen, R. H. Kerman, and B. D. Kahan. 1987. Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone. Am. J. Kidney Dis. 9:476-484.
264. Dummer, J. S., A. Hardy, A. Poorsattar, and M. Ho. 1983. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 36:259-267.
265. Starzl, T. E., M. A. Nalesnik, K. A. Porter, M. Ho, S. Iwatsuki, B. P. Griffith, J. T. Rosenthal, R. T. Hakala, B. W. Shaw, R. L. Hardesty, R. W. Atchison, R. Jaffe, and H. T. Bahson. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1:583-587.
266. Feutren G. 1992. The optimal use of cyclosporin A in autoimmune disease. J. Autoimmun. 5(Suppl. A):183-195.
267. Scott, J. R., L. E. Wagoner, S. L. Olsen, D. O. Taylor, and M. D. Renlund. 1993. Pregnancy in heart transplant recipients. Obstet. Gynecol. 82:324-327.
268. Pickrell, M. D., R. Sawers, and J. Michael. 1988. Pregnancy after renal transplantation: severe intrauterine growth retardation during treatment with cyclosporin A. B.M.J. 296:820-825.
269. Alegre, J., J. Teran, B. Alvarez, and J. L. Viejo. 1990. Successful use of cyclosporin for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis. Arthritis Rheum. 33:1594-1596.
270. York, E. L., T. Kovithavongs, A. S. Rebuck, and B. S. Sproule. 1990. Cyclosporin and chronic sarcoidosis. Chest 98:1026-1029.
271. Iacono, A. T., R. J. Keenan, and S. T. Juncan. 1996. Aerosolized cyclosporin in lung recipients with refractory chronic rejection. Am. J. Respir. Crit. Care Med. 153:1451-1455.
272. Keenan, R. J., A. Zeevi, A. T. Iacono, K. J. Spichty, J. Z. Cai, S. A. Yousem, N. P. Ohori, I. L. Paradis, A. Kawai, and B. P. Griffith. 1995. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 118:385-391.
273. Van Dooren-Greebe, R. J., A. L. Kuijpers, J. Mulder, T. De Boo, and P. C. van de Kerkhof. 1994. Methotrexate revisited: effects of long-term treatment in psoriasis. Br. J. Dermatol. 130:204-210.
274. Willkens, R. F., H. J. Williams, J. R. Ward, M. J. Egger, J. C. Reading, P. J. Clements, E. S. Cathcart, C. O. Samuelson, Jr., M. A. Solsky, and S. B. Kaplan. 1984. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 27:376-381.
275. Tugwell, P., K. Bennett, and M. Gent. 1987. Methotrexate in rheumatoid arthritis: indications, contraindications, efficacy, and safety. Ann. Intern. Med. 107:358-366.
276. Hamdy, H., R. J. R. McKendry, E. Mierins, and J. A. Liver. 1987. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a 24-week controlled clinical trial. Arthritis Rheum. 30:361-368.
277. Jeurissen, M. E., A. M. Boerbooms, L. B. van de Putte, W. H. Doesburg, and A. M. Lemmens. 1991. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. Ann. Intern. Med. 114:999-1004.
278. Weinblatt, M. E., B. N. Weissman, D. E. Holdsworth, P. A. Fraser, A. L. Maier, K. R. Falchuk, and J. S. Coblyn. 1992. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum. 35:129-137.
279. Williams, H. J., J. R. Ward, J. C. Reading, R. H. Brooks, D. O. Clegg, J. L. Skosey, M. H. Weisman, R. F. Willkens, J. Z. Singer, and G. S. Alarcon. 1992. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 35:259-269.
280. Hoffman, G. S., R. Y. Leavitt, G. S. Kerr, M. Rottem, M. C. Sneller, and A. S. Fauci. 1994. Treatment of glucocorticoid-resistant or relapsing Takayasu's arteritis with methotrexate. Arthritis Rheum. 37:578-582.
281. Krall, P. L., D. J. Mazanec, and W. S. Wilke. 1989. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleve. Clin. J. Med. 56:253-257.
282. Abud-Mendoza, C., A. K. Sturbaum, A. Vazquez-Compean, and R. Gonzalez-Amaro. 1993. Methotrexate therapy in childhood systemic lupus erythematosus. J. Rheumatol. 20:731-733.
283. Kaplan, M. M., T. A. Knox, and S. Arora. 1988. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann. Intern. Med. 109:429-431.
284. Feagan, B. G., J. Rochon, R. N. Fedorak, E. J. Irvine, G. Wild, L. Sutherland, A. S. Steinhart, G. R. Greenberg, R. Gillies, M. Hopkins, S. B. Hanauer, and J. W. D. McDonald. 1995. Methotrexate for the treatment of Crohn's disease. N. Engl. J. Med. 332:292-297.
285. Egan, L. J., and W. J. Sandborn. 1996. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin. Proc. 71:69-80.
286. Baughman, R. P., and E. E. Lower. 1990. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am. Rev. Respir. Dis. 142:1268-1271.
287. Soriano, F. B., P. Caramelli, R. Nitrini, and A. S. Rocha. 1990. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad. Med. J. 66:142-143.
288. Webster, G. F., L. K. Razsi, M. Sanchez, and J. L. Shupack. 1991. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J. Am. Acad. Dermatol. 24:451-454.
289. Cott, C. R. 1994. Perspective on methotrexate in the treatment of asthma (editorial). Chest 105:649-650.
290. Cronstein, B. N. 1992. Molecular mechanisms of methotrexate action in inflammation. Inflammation 16:411-423.
291. Kremer, J. M. 1994. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J. Rheumatol. 21:1-5.
292. Morgan, S. L., J. E. Baggott, W. H. Vaughn, P. K. Young, J. V. Austin, C. L. Krumdieck, and G. S. Alarcon. 1990. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 33:9-18.
293. Morgan, S. L., J. E. Baggott, W. H. Vaughn, J. S. Austin, T. A. Veitch, J. Y. Lee, W. J. Koopman, C. L. Krumdieck, and G. S. Alarcon. 1994. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann. Inter. Med. 121:833-841.
294. Furst, D. E., R. Koehnke, L. F. Burmeister, J. A. Kohler, and I. Cargill. 1989. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 16:313-320.
295. MacKinnon, S. K., G. Starkebaum, and R. F. Willkens. 1985. Pancytopenia associated with low-dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 15:119-126.
296. Roenigk, H. H., Jr., R. Auerbach, H. I. Maibach, and G. D. Weinstein. 1988. Methotrexate in psoriasis: revised guidelines. J. Am. Acad. Dermatol. 19:145-156.
297. Frenia, M. L., and K. S. Long. 1992. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. 26:234-237.
298. Furst, D. E., N. Erikson, L. Clute, R. Koehnke, L. F. Burmeister, and J. A. Kohler. 1990. Adverse experience with methotrexate during 176 weeks of a long-term, prospective trial in patients with rheumatoid arthritis. J. Rheumatol. 17:1628-1635.
299. Shirosky, J. B., C. Neville, J. M. Esdaile, et al. 1993. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 36:795-803.
300. Zachariae, H., K. Kragballe, and H. Sogaard. 1980. Methotrexate-induced liver cirrhosis: studies including serial biopsies during continued treatment. Br. J. Dermatol. 102:407-412.
301. Walker, A. M., D. Funch, N. A. Dreye, K. G. Tolman, et al. 1993. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 36: 329-335.
302. Warin, A. P., J. W. Landells, G. M. Levene, et al. 1975. A prospective study of the effects of weekly oral methotrexate on liver biopsy. Br. J. Dermatol. 93:321-327.
303. Kremer, J. M., G. S. Alarcon, R. W. Lightfoot, Jr., R. F. Willkens, D. E. Furst, H. J. Williams, P. B. Dent, and M. E. Weinblatt. 1994. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 37:316-328.
304. Lanse, S. B., G. L. Arnold, J. D. C. Gowans, and M. M. Kaplan. 1985. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. Dig. Dis. Sci. 30:104-109.
305. Erickson, A. R., V. Reddy, S. A. Vogelgesang, and S. G. West. 1995. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 38:1115-1119.
306. Bergquist, S. R., D. T. Felson, M. J. Prashker, and K. A. Freedberg. 1995. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 38:326-333.
307. Brick, J. E., L. W. Moreland, F. Al-Kawas, W. W. Chang, R. D. Layne, and A. G. DiBartolomeo. 1989. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin. Arthritis Rheum. 19:31-44.
308. Kremer, J. M., and C. T. Phelps. 1992. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum. 35:138-145.
309. Whiting-O'Keefe, Q. E., K. H. Fye, and K. D. Sack. 1991. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90:711-716.
310. Duhra, P. 1993. Treatment of gastrointestinal symptoms associated with methotrexate therapy for sarcoidosis. J. Am. Acad. Dermatol. 28:466-469.
311. Stewart, K. A., A. H. Mackenzie, J. D. Clough, and W. S. Wilke. 1991. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin. Arthritis Rheum. 20:332-338.
312. Cash, J. M., and J. H. Klippel. 1994. Second-line drug therapy for rheumatoid arthritis. N. Engl. J. Med. 330:1368-1375.
313. Carroll, G. J., R. Thomas, C. C. Phatouros, M. H. Atchison, A. L. Leslie, N. J. Cook, and I. D'Souza. 1994. Incidence, prevalence, and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J. Rheumatol. 21:51-54.
314. Searles, G., and R. J. McKendry. 1987. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J. Rheumatol. 14:1164-1171.
315. Hargreaves, M. R., A. G. Mowat, and M. K. Benson. 1992. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 47:628-633.
316. Dayton, C. S., D. A. Schwartz, N. L. Sprince, S. J. Yagla, C. S. Davis, R. K. Koehnke, D. E. Furst, and G. W. Hunninghake. 1995. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 151:1189-1193.
317. White, D. A., J. A. Rankin, D. E. Stover, R. A. Gellene, and S. Gupta. 1989. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am. Rev. Respir. Dis. 139:18-21.
318. Jones, G., E. Mierins, and J. Karsh. 1991. Methotrexate-induced asthma. Am. Rev. Respir. Dis. 143:179-181.
319. Weinblatt, M. E., and P. Fraser. 1989. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 32:1592-1596.
320. Thomas, D. R., J. S. Cover, and R. D. R. Camp. 1987. Pancytopenia induced by the interaction between methotrexate and trimethoprimsulfamethoxazole. J. Am. Acad. Dermatol. 17:1055-1056.
321. Weinblatt, M. E., H. Kaplan, B. F. Germain, S. Block, S. D. Solomon, R. C. Merriman, F. Wolfe, B. Wall, L. Anderson, E. Gall, et al. 1994. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum. 37:1492-1498.
322. Tugwell, P., K. Bennett, M. Bell, and M. Gent. 1989. Methotrexate in rheumatoid arthritis: feedback on American College of Physicians Guidelines. Ann. Intern. Med. 110:581-583.
323. Johansson, B. A. 1992. Visual field defects during low-dose methotrexate therapy. Doc. Ophthalmol. 79:91-94.
324. Thomas, E., J. I. Laroux, J. P. Hellier, and F. Blotman. 1993. Seizure and methotrexate therapy in RA. J. Rheumatol. 30:1623.
325. Shirosky, J. B., A. Frost, J. D. Skelton, D. G. Haegert, M. M. Newkirk, and C. Neville, 1991. Complications of immunosuppression associated with weekly low-dose methotrexate. J. Rheumatol. 18:1172-1175.
326. Stern, R. S., S. Zierler, and J. A. Parrish. 1982. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 50:869-872.
327. Nyfors, A., and H. Jensen. 1983. Frequency of malignant neoplasm in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica 167:260-262.
328. Kingsmore, S. F., B. D. Hall, N. B. Allen, J. R. Rice, and D. S. Caldwell. 1992. Association of methotrexate, rheumatoid arthritis, and lymphoma: report of 2 cases and literature review. J. Rheumatol. 19:1462-1465.
329. Hausknecht, R. U. 1995. Methotrexate and misoprostol to terminate early pregnancy. N. Engl. J. Med. 333:537-540.
330. Patsner, B., and D. Kenigsberg. 1988. Successful treatment of persistent ectopic pregnancy with oral methotrexate therapy. Fertil. Steril. 50:982-983.
331. Kozlowski, R. D., J. V. Steinbrunner, A. H. Mackenzie, J. D. Clough, W. S. Wilke, and A. M. Segal. 1990. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J. Med. 88:589-592.
332. Egarter, C. 1991. Methotrexate treatment of ectopic gestation and reproductive outcome. Am. J. Obstet. Gynecol. 164:698-699.
333. Feldkamp, M., and J. C. Carey. 1993. Clinical teratology counseling and consultation case report: low-dose methotrexate exposure in the early weeks of pregnancy. Teratology 47:533-539.
334. Evans, W. E., and M. L. Christensen. 1985. Drug interactions with methotrexate. J. Rheumatol. 12(Suppl. 12):15-20.
335. Blackburn, W. K., and G. S. Alarcon. 1989. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 32:1341-1342.
336. Weinblatt, M. E., A. L. Maier, and J. S. Coblyn. 1993. Low-dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week, randomized, placebo-controlled trial. J. Rheumatol. 20:950-952.
337. Joyce, D. A., R. K. Will, D. M. Hoffman, B. Laing, and S. J. Blackbourn. 1991. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann. Rheum. Dis. 50:913-914.
338. Tishler, M., D. Caspi, B. Fishel, and M. Yaron. 1988. The effects of leukocorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 31:906-908.
339. Deyer, P. D., T. R. Vaughan, and R. W. Weber. 1991. Methotrexate in the treatment of steroid-dependent asthma. J. Allergy Clin. Immunol. 88:208-212.
340. Stewart, G. E., J. D. Diaz, R. F. Lockey, M. J. Seleznick, W. L. Trudeau, and D. K. Ledford. 1994. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. J. Allergy Clin. Immunol. 94:482-489.
341. Lower, E. E., and R. P. Baughman. 1990. The use of low-dose methotrexate in refractory sarcoidosis. Am. J. Med. Sci. 299:153-157.
342. Sharma, O. P. 1993. Pulmonary sarcoidosis and corticosteroids. Am. Rev. Respir. Dis. 147:1598-1600.
343. O'Dell, J. R., C. E. Haire, N. Erikson, W. Drymalski, W. Palmer, P. J. Eckhoff, V. Garwood, P. Maloley, L. W. Klassen, S. Wees, H. Klein, and G. F. Moore. 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334: 1287-1291.
344. Tugwell, P., T. Pincus, D. Yocum, M. Stein, O. Gluck, G. Kraag, R. McKendry, J. Tesser, P. Baker, and G. Wells. 1995. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333:137-141.
345. Willkens, R. F., J. T. Sharp, D. Stablein, C. Marks, and R. Wortmann. 1995. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. Arthritis Rheum. 34:1799-1806.
346. Conaghan, P. G., and P. Brooks. 1995. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. Curr. Opin. Rheumatol. 7:167-173.
347. Tett, S. E. 1993. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin. Pharmacokinet. 25:392-407.
348. Clark, P., E. Casas, P. Tugwell, C. Medina, C. Gheno, G. Tenorio, and J. A. Orozco. 1993. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann. Intern. Med. 119:1067-1071.
349. Peters, D. H., A. Fitton, G. L. Plosker, and D. Faulds. 1993. Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 46:746-794.
350. Taylor, D. O., R. D. Ensley, S. L. Olsen, D. Dunn, and D. G. Renlund. 1994. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J. Heart Lung Transplant. 13:571-582.
351. Jones, E., and J. P. Callen. 1990. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J. Am. Acad. Dermatol. 23:487-489.
352. The HERA Study Group. 1995. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am. J. Med. 98:156-168.
353. van Schaardenburg, D., R. Valkema, B. A. Dijkmans, S. Papapoulos, A. H. Zwinderman, K. H. Han, E. K. Pauwels, and F. C. Breedveld. 1995. Prednisone treatment of elderly-onset rheumatoid arthritis: disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum. 38:334-342.